Opus Genetics Inc.
Organization details
- Legal name
- Opus Genetics Inc.
- Former names
- Ocuphire Pharma, Inc. Rexahn Pharmaceuticals, INC. Corporate Road Show DOT COM Inc Ferraro Frank
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Durham
- Headquarters state / province
- North Carolina
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- IRD
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001228627
- EIN
- 11-3516358
Board of directors
-
Adrienne L. Graves · DirectorSince 2024
-
Benjamin R. Yerxa · Director · PresidentSince 2024
-
Cam Gallagher · DirectorSince 2023
-
George Magrath · Director · Chief Executive OfficerSince 2025
-
James S. J. Manuso · DirectorSince 2023
-
Jay Pepose · DirectorSince 2023
-
Jean Bennett · DirectorSince 2024
-
Mina Sooch · Director · President and CEOSince 2023
-
Richard J. Rodgers · Director · Interim CEO and PresidentSince 2023
-
Sean Ainsworth · DirectorSince 2023
-
Susan Benton · DirectorSince 2023
Chief executives
Director election results
Annual meeting of April 20, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
96.2%
-
99.4%
-
99.4%
-
99.4%
-
99.4%
-
99.5%
-
99.5%
-
99.5%
-
99.5%
Board connections
5 of this board's directors also sit on 8 other boards. 8 are in the same sector.
-
Ardelyx Inc. Same sectorvia Richard J. Rodgers
-
Harrow Inc. Same sectorvia Adrienne L. Graves
-
Novavax Inc. Same sectorvia Richard J. Rodgers
-
Ocular Therapeutix Inc. Same sectorvia Adrienne L. Graves
-
REGENXBIO Inc. Same sectorvia Jean Bennett
-
Sagimet Biosciences Inc. Same sectorvia Richard J. Rodgers
-
TuHURA Biosciences Inc. Same sectorvia James S. J. Manuso
-
Zentalis Pharmaceuticals Inc. Same sectorvia Cam Gallagher
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $323,890
- 2 purchases by 1 insider
- Sold, last 12 months
- $19,675,584
- 24 sales by 7 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 3, 2026 | George Magrath Director, Officer (Chief Executive Officer) | Open-market sale | −28,258 | $3.90 | $110,184 |
| Oct 23, 2026 | Robert E. Gagnon Officer (Chief Financial Officer) | Open-market sale | −14,000 | $3.55 | $49,650 |
| Oct 23, 2026 | George Magrath Director, Officer (Chief Executive Officer) | Open-market sale | −9,591 | $3.59 | $34,384 |
| Oct 23, 2026 | Benjamin R. Yerxa Director, Officer (President) | Open-market sale | −7,669 | $3.55 | $27,236 |
| Oct 23, 2026 | SCHACHLE JOSEPH K Officer (Chief Operating Officer) | Open-market sale | −4,767 | $3.57 | $16,994 |
| Oct 23, 2026 | Benjamin R. Yerxa Director, Officer (President) | Open-market sale | −25,520 | $3.53 | $90,129 |
| Sep 30, 2026 | Foundation Fighting Blindness Retinal Degeneration Fund Director, See Remarks | Open-market sale | −556,000 | $4.96 | $2,755,981 |
| Sep 9, 2026 | George Magrath Director, Officer (Chief Executive Officer) | Option exercise | +392,157 | $1.15 | $450,981 |
| Sep 9, 2026 | George Magrath Director, Officer (Chief Executive Officer) | Shares withheld for tax | −75,541 | $5.97 | $450,980 |
| Sep 8, 2026 | Cam Gallagher Director | Option exercise | +784,314 | $1.15 | $901,961 |
| Sep 3, 2026 | Robert E. Gagnon Officer (Chief Financial Officer) | Open-market sale | −28,000 | $4.54 | $127,120 |
| Jul 23, 2026 | Robert E. Gagnon Officer (Chief Financial Officer) | Open-market sale | −7,783 | $2.95 | $22,960 |
| Jul 23, 2026 | George Magrath Director, Officer (Chief Executive Officer) | Open-market sale | −9,475 | $2.95 | $27,951 |
| Jul 23, 2026 | SCHACHLE JOSEPH K Officer (Chief Operating Officer) | Open-market sale | −4,644 | $2.94 | $13,653 |
| Jul 23, 2026 | Benjamin R. Yerxa Director, Officer (President) | Open-market sale | −7,429 | $2.97 | $22,064 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Opus Genetics Inc.
Who is the CEO of Opus Genetics Inc.?
Mina Sooch is Opus Genetics Inc.'s President and CEO.
How many directors are on Opus Genetics Inc.'s board?
Opus Genetics Inc.'s board has 11 directors: Adrienne L. Graves, Benjamin R. Yerxa, Cam Gallagher, George Magrath, James S. J. Manuso, Jay Pepose, Jean Bennett, Mina Sooch, Richard J. Rodgers, Sean Ainsworth and 1 other.
Are Opus Genetics Inc. insiders buying or selling shares?
Over the last 12 months, Opus Genetics Inc. insiders bought $323,890 of shares in 2 purchases and sold $19.7 million of shares in 24 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="opus-genetics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.